Cogent Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
COGT$33.54+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $312,012 | $98,165 |
| Short-term marketable securities | 588,753 | 188,912 |
| Prepaid expenses and other current assets | 9,590 | 9,395 |
| Total current assets | 910,355 | 296,472 |
| Operating lease, right-of-use assets | 18,078 | 20,097 |
| Property and equipment, net | 5,457 | 6,467 |
| Restricted cash | 416 | — |
| Other assets | 3,301 | 4,862 |
| Total assets | $937,607 | $327,898 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $9,504 | $12,013 |
| Accrued expenses and other current liabilities | 52,902 | 42,132 |
| Operating lease liabilities | 1,547 | 1,565 |
| Total current liabilities | 63,953 | 55,710 |
| Convertible senior notes, net | 222,895 | — |
| Operating lease liabilities, net of current portion | 14,355 | 15,902 |
| Other liabilities | 33 | — |
| Total liabilities | 301,236 | 71,612 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 8,979,420 shares authorized; no shares issued or outstanding | — | — |
| Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 67,414 and 70,465 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 53,830 | 56,515 |
| Series B non-voting convertible preferred stock, $0.001 par value; 20,580 shares authorized; 4,516 and 6,868 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 35,563 | 54,085 |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 160,980,024 shares and 110,461,729 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 161 | 110 |
| Additional paid-in capital | 1,734,882 | 1,004,612 |
| Accumulated other comprehensive income | 355 | 447 |
| Accumulated deficit | (1,188,420) | (859,483) |
| Total stockholders’ equity | 636,371 | 256,286 |
| Total liabilities and stockholders’ equity | $937,607 | $327,898 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.